Bioscience is one of Connecticut Innovations’ most active investment areas.

Connecticut’s strong bioscience infrastructure supports entrepreneurial companies and creates many opportunities for investment. This infrastructure includes: world-class research facilities at the University of Connecticut and Yale University, which have spun out several bioscience companies CI has invested in; operations of major pharmaceutical companies such as Bristol-Myers Squibb, Boehringer Ingelheim and Pfizer; more than 35 private and publicly held emerging bioscience companies; and, CURE, the educational and business support network organization for bioscience in the state.

The state’s bioscience cluster is also strengthened by Connecticut’s $100 million Stem Cell Research Grants Program and a full complement of tax and other financing incentives for early-stage bioscience ventures.



“In 2009, Soft Tissue Regeneration, originally based in Virginia, decided to relocate to Connecticut based partially on an investment Connecticut Innovations made in our company, but, more important, the decision was based on the professionalism of the CI team and their in-depth experience in dealing with and mentoring startup enterprises.” – Joseph Reilly, President, CEO and Founder, Soft Tissue Regeneration Inc.

“We are very excited to be partnering with CI and feel fortunate to have their confidence and support. The funding provided by CI, and all of our investors, is enabling us to move forward with our mission to develop next-generation life science tools.” – Per Hellsund, Founder, President and CEO, CyVek Inc.